Cargando…
Evaluating different breast tumor progression models using screening data
BACKGROUND: Mammography screening is used to detect breast cancer at an early treatable stage, reducing breast cancer mortality. Traditionally, breast cancer has been seen as a disease with only progressive lesions, and here we examine the validity of this assumption by testing if incidence levels a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819671/ https://www.ncbi.nlm.nih.gov/pubmed/29463227 http://dx.doi.org/10.1186/s12885-018-4130-2 |
_version_ | 1783301248244514816 |
---|---|
author | Westvik, Åsbjørn Schumacher Weedon-Fekjær, Harald Mæhlen, Jan Liestøl, Knut |
author_facet | Westvik, Åsbjørn Schumacher Weedon-Fekjær, Harald Mæhlen, Jan Liestøl, Knut |
author_sort | Westvik, Åsbjørn Schumacher |
collection | PubMed |
description | BACKGROUND: Mammography screening is used to detect breast cancer at an early treatable stage, reducing breast cancer mortality. Traditionally, breast cancer has been seen as a disease with only progressive lesions, and here we examine the validity of this assumption by testing if incidence levels after introducing mammography screening can be reproduced assuming only progressive tumors. METHODS: Breast cancer incidence data 1990–2009 obtained from the initially screened Norwegian counties (Akershus, Oslo, Rogaland and Hordaland) was included, covering the time-period before, during and after the introduction of mammography screening. From 1996 women aged 50–69 were invited for biennial public screening. Using estimates of tumor growth and screening sensitivity based on pre-screening and prevalence screening data (1990–1998), we simulated incidence levels during the following period (1999–2009). RESULTS: The simulated incidence levels during the period with repeated screenings were markedly below the observed levels. The results were robust to changes in model parameters. Adjusting for hormone replacement therapy use, we obtained levels closer to the observed levels. However, there was still a marked gap, and only by assuming some tumors that undergo regressive changes or enter a markedly less detectable state, was our model able to reproduce the observed incidence levels. CONCLUSIONS: Models with strictly progressive tumors are only able to partly explain the changes in incidence levels observed after screening introduction in the initially screened Norwegian counties. More complex explanations than a time shift in detection of future clinical cancers seem to be needed to reproduce the incidence trends, questioning the basis for many over-diagnosis calculations. As data are not randomized, similar studies in other populations are wanted to exclude effect of unknown confounders. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-4130-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5819671 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-58196712018-02-26 Evaluating different breast tumor progression models using screening data Westvik, Åsbjørn Schumacher Weedon-Fekjær, Harald Mæhlen, Jan Liestøl, Knut BMC Cancer Research Article BACKGROUND: Mammography screening is used to detect breast cancer at an early treatable stage, reducing breast cancer mortality. Traditionally, breast cancer has been seen as a disease with only progressive lesions, and here we examine the validity of this assumption by testing if incidence levels after introducing mammography screening can be reproduced assuming only progressive tumors. METHODS: Breast cancer incidence data 1990–2009 obtained from the initially screened Norwegian counties (Akershus, Oslo, Rogaland and Hordaland) was included, covering the time-period before, during and after the introduction of mammography screening. From 1996 women aged 50–69 were invited for biennial public screening. Using estimates of tumor growth and screening sensitivity based on pre-screening and prevalence screening data (1990–1998), we simulated incidence levels during the following period (1999–2009). RESULTS: The simulated incidence levels during the period with repeated screenings were markedly below the observed levels. The results were robust to changes in model parameters. Adjusting for hormone replacement therapy use, we obtained levels closer to the observed levels. However, there was still a marked gap, and only by assuming some tumors that undergo regressive changes or enter a markedly less detectable state, was our model able to reproduce the observed incidence levels. CONCLUSIONS: Models with strictly progressive tumors are only able to partly explain the changes in incidence levels observed after screening introduction in the initially screened Norwegian counties. More complex explanations than a time shift in detection of future clinical cancers seem to be needed to reproduce the incidence trends, questioning the basis for many over-diagnosis calculations. As data are not randomized, similar studies in other populations are wanted to exclude effect of unknown confounders. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-4130-2) contains supplementary material, which is available to authorized users. BioMed Central 2018-02-20 /pmc/articles/PMC5819671/ /pubmed/29463227 http://dx.doi.org/10.1186/s12885-018-4130-2 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Westvik, Åsbjørn Schumacher Weedon-Fekjær, Harald Mæhlen, Jan Liestøl, Knut Evaluating different breast tumor progression models using screening data |
title | Evaluating different breast tumor progression models using screening data |
title_full | Evaluating different breast tumor progression models using screening data |
title_fullStr | Evaluating different breast tumor progression models using screening data |
title_full_unstemmed | Evaluating different breast tumor progression models using screening data |
title_short | Evaluating different breast tumor progression models using screening data |
title_sort | evaluating different breast tumor progression models using screening data |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819671/ https://www.ncbi.nlm.nih.gov/pubmed/29463227 http://dx.doi.org/10.1186/s12885-018-4130-2 |
work_keys_str_mv | AT westvikasbjørnschumacher evaluatingdifferentbreasttumorprogressionmodelsusingscreeningdata AT weedonfekjærharald evaluatingdifferentbreasttumorprogressionmodelsusingscreeningdata AT mæhlenjan evaluatingdifferentbreasttumorprogressionmodelsusingscreeningdata AT liestølknut evaluatingdifferentbreasttumorprogressionmodelsusingscreeningdata |